+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Gastric and Gastroesophageal Junction Adenocarcinoma - Epidemiology Forecast to 2029

  • ID: 5147746
  • Report
  • September 2020
  • Region: Global
  • 57 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Gastric and Gastroesophageal Junction Adenocarcinoma - Epidemiology Forecast to 2029

Summary

Gastric cancer, also known as stomach cancer, occurs when cancer cells form in the lining of the stomach. Approximately 90% to 95% of gastric cancer cases are considered to be an adenocarcinoma, a cancer that develops in the mucosa - the innermost layer of the stomach. Gastric cancer usually develops slowly and rarely shows any signs or symptoms in the early stages. The majority of gastric cancer cases are diagnosed at an advanced stage. Symptoms of gastric cancer can include poor appetite, weight loss, abdominal pain, nausea, blood in the stool, and vomiting.

The publisher epidemiologists used age- and sex-specific diagnosed incidence rates to forecast the diagnosed incident cases, and used the observed survival rates to calculate the five-year diagnosed prevalent cases. The diagnosed incidence rates were supported by age- and sex-specific incidence data drawn from national cancer registries for markets where data were available. the publisher's epidemiologists applied country-specific incidence rates of gastric cancer to each country’s population to obtain the number of estimated diagnosed incident cases.

The following data describes epidemiology of gastric cancer, including gastric and GEJ adenocarcinoma cases. In 2019, the 8MM had 251,366 diagnosed incident cases of gastric cancer. This is expected to increase to 284,638 diagnosed incident cases of 2029, at an Annual Growth Rate (AGR) of 1.32%. The increase is driven by the aging population in the 8MM. In 2019, the 8MM had 698,947 diagnosed prevalent cases of gastric cancer. This is expected to increase to 793,987 diagnosed prevalent cases of 2029, at an AGR of 1.36%. Japan had the highest number of diagnosed incident and diagnosed prevalent cases of gastric cancer. The accompanying epidemiology model includes additional analysis on the diagnosed incident cases of GEJ adenocarcinoma.

Scope
  • Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma Epidemiology Report provides an overview of the risk factors and global trends of gastric and GEJ cancer in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and South Korea).
  • This report also includes a 10-year epidemiological forecast for the following segmentations in all ages across the 8MM: diagnosed incident cases of gastric cancer; five-year diagnosed prevalent cases of gastric cancer; diagnosed incident cases of gastric cancer by stage at diagnosis (IA, IB, II, IIIA, IIIB, IIIC, and IV) and mutations and biomarkers; diagnosed incident cases of GEJ cancer, diagnosed incident of gastric cancer (excluding GEJ), and diagnosed incident cases of gastric adenocarcinoma.
  • The Gastric and GEJ Adenocarcinoma Epidemiology Report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.
Reasons to Buy

The Gastric and GEJ Adenocarcinoma Epidemiology series will allow you to -
  • Develop business strategies by understanding the trends shaping and driving the global gastric and GEJ adenocarcinoma market.
  • Quantify patient populations in the global gastric and GEJ adenocarcinoma market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups that present the best opportunities for gastric and GEJ adenocarcinoma therapeutics in each of the markets covered.
  • Understand magnitude gastric and GEJ adenocarcinoma market by stage, mutations and biomarkers.
Note: Product cover images may vary from those shown
1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Gastric Cancer: Executive Summary
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Reports

3 Epidemiology
3.1 Disease Background
3.2 Risk Factors
3.3 Global and Historical Trends
3.3.1 8MM Trends in the Diagnosed Incidence
3.4 Forecast Methodology
3.4.1 Sources
3.4.2 Forecast Assumptions and Methods
3.5 Epidemiological Forecast for Gastric Cancer (2019-2029)
3.5.1 Diagnosed Incident Cases of Gastric Cancer
3.5.2 Age-Specific Diagnosed Incident Cases of Gastric Cancer
3.5.3 Sex-Specific Diagnosed Incident Cases of Gastric Cancer
3.5.4 Five-Year Diagnosed Prevalent Cases of Gastric Cancer
3.5.5 Diagnosed Incident Cases of Gastric Cancer by Stage at Diagnosis
3.5.6 Diagnosed Incident Cases of Gastric Cancer with HER-2 Overexpression
3.5.7 Diagnosed Incident Cases of Gastric Cancer with PD-L1 Expression
3.5.8 Diagnosed Incident Cases of Gastric Cancer with MSI
3.5.9 Diagnosed Incident Cases of Gastric Cancer with NTRK Gene Fusions
3.5.10 Diagnosed Incident Cases of GEJ Cancer
3.5.11 Diagnosed Incident Cases of Gastric Cancer, excluding GEJ Cancer
3.5.12 Diagnosed Incident Cases of Gastric Adenocarcinoma
3.6 Discussion
3.6.1 Epidemiological Forecast Insight
3.6.2 COVID-19 Impact
3.6.3 Limitations of Analysis
3.6.4 Strengths of Analysis

4 Appendix
4.1 Bibliography
4.2 About the Authors
4.2.1 Epidemiologist
4.2.2 Reviewers
4.2.3 Global Director of Therapy Analysis and Epidemiology
4.2.4 Global Head and EVP of Healthcare Operations and Strategy
4.3 About the Publisher
4.4 Contact
4.5 Disclaimer

List of Tables
Table 1: Summary of Newly Added Data Types and Countries and Different Segments
Table 2: Summary of Updated Data Types
Table 3: Risk Factors for Gastric Cancer

List of Figures
Figure 1: 8MM, Diagnosed Incident Cases of Gastric Cancer, Men and Women, Ages ≥20 Years, 2019 and 2029, N
Figure 2: 8MM, Five-year Diagnosed Prevalent Cases of Gastric Cancer, Men and Women, Ages ≥20 Years, 2019 and 2029, N
Figure 3: 8MM, Diagnosed Incidence of Gastric Cancer, Men, Ages ≥20 Years, 2009-2029, Cases Per 100,000 Population
Figure 4: 8MM, Diagnosed Incidence of Gastric Cancer, Women, Ages ≥20 Years, 2009-2029, Cases Per 100,000 Population
Figure 5: Sources Used and Not Used for Diagnosed Incident Cases of Gastric Cancer
Figure 6: Sources Used for Diagnosed Incident Cases of Gastric Cancer by Stage at Diagnosis
Figure 7: Sources Used for Five-Year Diagnosed Prevalent Cases of Gastric Cancer
Figure 8: Sources Used for Diagnosed Incident Cases of Gastric Cancer with HER-2 Overexpression
Figure 9: Sources Used for Diagnosed Incident Cases of Gastric Cancer with PD-L1 Expression
Figure 10: Sources Used for Diagnosed Incident Cases of Gastric Cancer with MSI
Figure 11: Sources Used for Diagnosed Incident Cases of Gastric Cancer with NTRK Gene Fusions
Figure 12: Sources Used for Diagnosed Incident Cases of GEJ Cancer
Figure 13: Sources Used for Diagnosed Incident Cases of Gastric Cancer, excluding GEJ Cancer
Figure 14: Sources Used for Diagnosed Incident Cases of Gastric Adenocarcinoma
Figure 15: 8MM, Diagnosed Incident Cases of Gastric Cancer, Men and Women, Ages ≥20 Years, 2019
Figure 16: 8MM, Age-Specific Diagnosed Incident Cases of Gastric Cancer, Men and Women, Ages ≥20 Years, 2019
Figure 17: 8MM, Sex-Specific Diagnosed Incident Cases of Gastric Cancer, Men and Women, Ages ≥20 Years, 2019, N
Figure 18: 8MM, Five-Year Diagnosed Prevalent Cases of Gastric Cancer, Men and Women, Ages ≥20 Years, 2019
Figure 19: 8MM, Diagnosed Incident Cases of Gastric Cancer by Stage at Diagnosis, Men and Women, Ages ≥20 Years, 2019
Figure 20: 8MM, Diagnosed Incident Cases of Gastric Cancer with HER-2 Overexpression, Men and Women, Ages ≥20 Years, 2019
Figure 21: 8MM, Diagnosed Incident Cases of Gastric Cancer with PD-L1 Expression, Men and Women, Ages ≥20 Years, 2019
Figure 22: 8MM, Diagnosed Incident Cases of Gastric Cancer with MSI, Men and Women, Ages ≥20 Years, 2019
Figure 23: 8MM, Diagnosed Incident Cases of Gastric Cancer with NTRK Gene Fusions, Men and Women, Ages ≥20 Years, 2019
Figure 24: 8MM, Diagnosed Incident Cases of GEJ Cancer, Men and Women, Ages ≥20 Years, 2019
Figure 25: 8MM, Diagnosed Incident Cases of Gastric Cancer, excluding GEJ Cancer, Men and Women, Ages ≥20 Years, 2019
Figure 26: 8MM, Diagnosed Incident Cases of Gastric Adenocarcinoma, Men and Women, Ages ≥20 Years, 2019
Note: Product cover images may vary from those shown
Adroll
adroll